In a groundbreaking move, Cellares, the pioneering Integrated Development and Manufacturing Organization (IDMO) with a focus on large-scale cell therapy production, has made a significant announcement. The global biopharmaceutical titan Bristol Myers Squibb (NYSE: BMY), known for its leadership in cell therapy, is set to embark on a second proof-of-concept tech transfer process. This venture is aimed at the production of CAR-T cell therapy and is a part of the innovative Cellares Technology Adoption Partnership (TAP) program. "As part of this expanded agreement, Cellares will optimize, automate, and tech-transfer the additional CAR-T cell therapy process onto its automated manufacturing platform, the Cell Shuttle," the announcement read.

The TAP program by Cellares isn't just another initiative. It represents a swift, low-risk gateway for cell therapy innovators to embrace the company's state-of-the-art automated manufacturing tech for their upcoming products. Bristol Myers Squibb is not just participating but actively assessing the Cell Shuttle's potential as an automated manufacturing method. Their goal? To generate data that underscores the Cell Shuttle's credentials as an efficient, scalable, and cost-effective manufacturing solution for cell therapies. The buzz around Cellares is palpable, with the TAP program witnessing a surge in demand. Top-tier cell therapy developers are eager to integrate the Cell Shuttle into their clinical and commercial-stage GMP manufacturing processes.

Cellares CEO Fabian Gerlinghaus expressed his enthusiasm, stating, “We’re excited to expand our relationship with Bristol Myers Squibb even further beyond the Series C investment and the first TAP program for cell therapies. The optimization and automation of this additional CAR-T cell therapy process through our TAP program expands on our first partnership with BMS and helps our mission to accelerate access to life-saving cell therapies for patients.”

Diving deeper into the technicalities, Cellares' avant-garde manufacturing tech is versatile, catering to both autologous and allogeneic cell therapy processes and covering a whopping 90% of cell therapy modalities. The TAP program is transformative. Manual processes can metamorphose and be tech-transferred to the Cell Shuttle platform in a mere six months. And for cell therapy developers, the flexibility is unmatched. They can tech-transfer their processes to a Cell Shuttle at any juncture, be it during the pre-clinical phase, clinical trials, or post-regulatory green light. The cherry on top? Thanks to the marvels of automation, standardization, and software-defined manufacturing (SDM), every subsequent tech transfer is instantaneous, irrespective of the Cell Shuttle's location in any IDMO Smart Factory globally.